Antigen Spreading Mediates Heterogeneous Solid Tumor Eradication by DNA Demethylating Agent-Programmed CAR T Cells

Investigators highlighted the potent antitumor activity of low-dose decitabine-primed CAR T cells (dCAR T) in solid tumor models, a benefit previously confirmed in hematologic malignancies. dCAR T cell infusion in immunocompetent mice led to elimination of mixed tumor masses containing, without the need for prior lymphodepletion.